Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
UNICANCER
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07359456CT.gov Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases | — | Not Yet Recruiting | — | — | — |
NCT07363408CT.gov Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07284394CT.gov Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease | — | Not Yet Recruiting | — | — | — |
NCT07318389CT.gov ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07381309CT.gov Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM | — | Not Yet Recruiting | — | — | — |
NCT07621497CT.gov FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) | — | Not Yet Recruiting | — | — | — |
NCT07515963CT.gov FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases. | — | Not Yet Recruiting | — | — | — |
NCT07570914CT.gov Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | — | Not Yet Recruiting | — | — | — |
NCT07525206CT.gov A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07585279CT.gov A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
Show 476 more trialsShow fewer
NCT07500298CT.gov Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07527858CT.gov Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT07604909CT.gov A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy | — | Recruiting | — | — | — |
NCT07549412CT.gov A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) | — | Recruiting | — | — | — |
NCT07503756CT.gov JS212 Combination Therapies in Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07094893CT.gov Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status | — | Not Yet Recruiting | — | — | — |
NCT07474727CT.gov A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07391566CT.gov LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation | — | Not Yet Recruiting | — | — | — |
NCT07381764CT.gov ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer" | — | Not Yet Recruiting | — | — | — |
NCT07284849CT.gov A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | — | Recruiting | — | — | — |
NCT07323576CT.gov A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer | — | Withdrawn | — | — | — |
NCT07395063CT.gov A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond. | — | Not Yet Recruiting | — | — | — |
NCT07229846CT.gov A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | — | Not Yet Recruiting | — | — | — |
NCT07353268CT.gov Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy. | — | Not Yet Recruiting | — | — | — |
NCT07150403CT.gov Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07221357CT.gov A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07318805CT.gov A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT06948448CT.gov A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT06856837CT.gov - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases | — | Recruiting | — | — | — |
NCT07407465CT.gov Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. | — | Recruiting | — | — | — |
NCT07389265CT.gov Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07134205CT.gov The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07011576CT.gov A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL) | — | Recruiting | — | — | — |
NCT06501989CT.gov Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer | — | Withdrawn | — | — | — |
NCT07134101CT.gov Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01) | — | Not Yet Recruiting | — | — | — |
NCT07123441CT.gov A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07106034CT.gov Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial | — | Not Yet Recruiting | — | — | — |
NCT07011550CT.gov Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer | — | Suspended | — | — | — |
NCT07021950CT.gov AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07079631CT.gov A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT06867822CT.gov Trial of ProAgio in Advanced/Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06974110CT.gov Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT07059338CT.gov Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07051785CT.gov Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07309289CT.gov NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07025239CT.gov QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06501482CT.gov Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI | — | Recruiting | — | — | — |
NCT07009145CT.gov QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC | — | Not Yet Recruiting | — | — | — |
NCT06696768CT.gov Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07150247CT.gov Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06963502CT.gov A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT07020468CT.gov Neoadjuvant Therapy （NALIRIFOX） for Locally Advanced Colon and Upper Rectal Cancer | — | Active Not Recruiting | — | — | — |
NCT07204574CT.gov The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06887218CT.gov 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT03401294CT.gov Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. | — | Recruiting | — | — | — |
NCT06855849CT.gov An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment. | — | Not Yet Recruiting | — | — | — |
NCT06820463CT.gov A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07543744CT.gov A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI | — | Recruiting | — | — | — |
NCT06922383CT.gov A Clinical Study of Arfolitixorin in Patients With mCRC | — | Recruiting | — | — | — |
NCT06899477CT.gov Pre-Operative Treatment in REseCTable COlon CanceR | — | Not Yet Recruiting | — | — | — |
NCT06917079CT.gov BBO-11818 in Adult Subjects With KRAS Mutant Cancer | — | Recruiting | — | — | — |
NCT06784947CT.gov Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT06245356CT.gov Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer | — | Recruiting | — | — | — |
NCT06838338CT.gov JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC | — | Active Not Recruiting | — | — | — |
NCT06792695CT.gov A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | — | Recruiting | — | — | — |
NCT06835569CT.gov A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | — | Recruiting | — | — | — |
NCT06621563CT.gov Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06497985CT.gov A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients | — | Recruiting | — | — | — |
NCT06268015CT.gov Botensilimab and Balstilimab Optimization in Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT06733038CT.gov FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. | — | Recruiting | — | — | — |
NCT06643793CT.gov Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC | — | Recruiting | — | — | — |
NCT06625775CT.gov Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06607185CT.gov A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06825624CT.gov ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06586515CT.gov MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | — | Recruiting | — | — | — |
NCT06493760CT.gov A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients | — | Recruiting | — | — | — |
NCT07047560CT.gov Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study | — | Recruiting | — | — | — |
NCT06575127CT.gov Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study | — | Recruiting | — | — | — |
NCT06341309CT.gov Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06252649CT.gov Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation | — | Recruiting | — | — | — |
NCT06443307CT.gov Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan | — | Recruiting | — | — | — |
NCT06341296CT.gov Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06434090CT.gov Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06640166CT.gov Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. | — | Recruiting | — | — | — |
NCT06881537CT.gov CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer | — | Recruiting | — | — | — |
NCT06445062CT.gov Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | — | Recruiting | — | — | — |
NCT06411600CT.gov Combination Therapy for BRAF-V600E Metastatic CRCm | — | Recruiting | — | — | — |
NCT06448364CT.gov A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination | — | Terminated | — | — | — |
NCT06405139CT.gov Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT06423937CT.gov Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06192680CT.gov Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06525428CT.gov Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06225622CT.gov Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT06321081CT.gov ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC | — | Recruiting | — | — | — |
NCT06106308CT.gov Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | — | Active Not Recruiting | — | — | — |
NCT06280495CT.gov Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients | — | Recruiting | — | — | — |
NCT06004245CT.gov A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06089330CT.gov A Study of JMT101 in Patients With Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT06184698CT.gov Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06039202CT.gov Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05999812CT.gov Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT06011772CT.gov EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05722327CT.gov Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05839470CT.gov Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer | — | Unknown | — | — | — |
NCT06107413CT.gov Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | — | Active Not Recruiting | — | — | — |
NCT05959356CT.gov Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06099951CT.gov Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy | — | Not Yet Recruiting | — | — | — |
NCT06047379CT.gov Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | — | Recruiting | — | — | — |
NCT06060704CT.gov Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC. | — | Unknown | — | — | — |
NCT05863195CT.gov Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | — | Recruiting | — | — | — |
NCT05854498CT.gov Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05983367CT.gov A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT05962502CT.gov Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy | — | Recruiting | — | — | — |
NCT05843188CT.gov Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05824559CT.gov ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT05954078CT.gov Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer | — | Recruiting | — | — | — |
NCT05969899CT.gov Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05571644CT.gov Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT05733611CT.gov RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | — | Terminated | — | — | — |
NCT05555901CT.gov The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05824975CT.gov A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | — | Recruiting | — | — | — |
NCT05919264CT.gov FOG-001 in Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05462613CT.gov Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05846867CT.gov A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05627635CT.gov FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05585814CT.gov CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer | — | Recruiting | — | — | — |
NCT05839951CT.gov An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions | — | Completed | — | — | — |
NCT05861505CT.gov COLLISION RELAPSE Trial | — | Recruiting | — | — | — |
NCT05678257CT.gov A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer | — | Terminated | — | — | — |
NCT05786924CT.gov Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | — | Recruiting | — | — | — |
NCT05462236CT.gov MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05799443CT.gov Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer | — | Unknown | — | — | — |
NCT05593328CT.gov Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation | — | Completed | — | — | — |
NCT05732129CT.gov The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer. | — | Unknown | — | — | — |
NCT05652894CT.gov A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05721872CT.gov Efficacy, Tolerability and Safety of Intravenous D-VC With ATO in Patients With Advanced/Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT06307249CT.gov Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA | — | Recruiting | — | — | — |
NCT05684211CT.gov A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT05634590CT.gov The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05277766CT.gov Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer | — | Recruiting | — | — | — |
NCT05427669CT.gov Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD) | — | Not Yet Recruiting | — | — | — |
NCT06048146CT.gov A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis | — | Completed | — | — | — |
NCT06202001CT.gov Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients | — | Recruiting | — | — | — |
NCT05489211CT.gov Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | — | Recruiting | — | — | — |
NCT05480306CT.gov Phase 2 Study of DKN-01 in Colorectal Cancer | — | Completed | — | — | — |
NCT05522738CT.gov Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05453825CT.gov A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | — | Unknown | — | — | — |
NCT05464030CT.gov Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | — | Recruiting | — | — | — |
NCT06403709CT.gov Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients | — | Active Not Recruiting | — | — | — |
NCT05379595CT.gov A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05278351CT.gov Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC | — | Unknown | — | — | — |
NCT05435313CT.gov Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy | — | Unknown | — | — | — |
NCT05330429CT.gov Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) | — | Terminated | — | — | — |
NCT05382442CT.gov A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05353582CT.gov Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases | — | Unknown | — | — | — |
NCT05314101CT.gov TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer | — | Unknown | — | — | — |
NCT05229003CT.gov Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC | — | Recruiting | — | — | — |
NCT05978349CT.gov PTC Drug Sensitivity Detection to Guide Postoperative Adjuvant of Colorectal Cancer | — | Unknown | — | — | — |
NCT05171660CT.gov Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05200299CT.gov mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer | — | Unknown | — | — | — |
NCT03678428CT.gov FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM | — | Terminated | — | — | — |
NCT05007132CT.gov Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05008809CT.gov Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) | — | Recruiting | — | — | — |
NCT05039944CT.gov SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies | — | Terminated | — | — | — |
NCT04952753CT.gov Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC | — | Terminated | — | — | — |
NCT05084859CT.gov A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT02942706CT.gov Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC | — | Unknown | — | — | — |
NCT05103020CT.gov Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases | — | Unknown | — | — | — |
NCT05005403CT.gov Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan | — | Recruiting | — | — | — |
NCT04929223CT.gov A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | — | Recruiting | — | — | — |
NCT04847063CT.gov Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies | — | Recruiting | — | — | — |
NCT05029882CT.gov Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | — | Active Not Recruiting | — | — | — |
NCT05068206CT.gov A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx | — | Unknown | — | — | — |
NCT06540261CT.gov The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05004350CT.gov A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT04920032CT.gov Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas | — | Recruiting | — | — | — |
NCT04535401CT.gov Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines | — | Unknown | — | — | — |
NCT04912258CT.gov Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis | — | Unknown | — | — | — |
NCT04793958CT.gov Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | — | Active Not Recruiting | — | — | — |
NCT04929652CT.gov Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT04999761CT.gov AB122 Platform Study | — | Recruiting | — | — | — |
NCT04854668CT.gov A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT04660812CT.gov An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT04761614CT.gov Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT04657068CT.gov A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT04687631CT.gov Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases | — | Recruiting | — | — | — |
NCT06547385CT.gov Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT04668976CT.gov A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | — | Unknown | — | — | — |
NCT04587128CT.gov Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC | — | Active Not Recruiting | — | — | — |
NCT04659382CT.gov Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT04525326CT.gov Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases | — | Unknown | — | — | — |
NCT04553692CT.gov Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | — | Terminated | — | — | — |
NCT04527068CT.gov QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT04392479CT.gov TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study. | — | Unknown | — | — | — |
NCT04164069CT.gov Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab | — | Completed | — | — | — |
NCT04230187CT.gov Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT04456699CT.gov Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) | — | Completed | — | — | — |
NCT04449874CT.gov A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | — | Active Not Recruiting | — | — | — |
NCT04337879CT.gov A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT04446091CT.gov A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC) | — | Unknown | — | — | — |
NCT04247256CT.gov A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI | — | Unknown | — | — | — |
NCT04397601CT.gov Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT04513951CT.gov AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients | — | Completed | — | — | — |
NCT04338191CT.gov mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT04117945CT.gov Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT04126655CT.gov Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and Calciumfolinate | — | Unknown | — | — | — |
NCT04224415CT.gov Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC | — | Completed | — | — | — |
NCT04256707CT.gov Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment | — | Completed | — | — | — |
NCT04189055CT.gov Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. | — | Unknown | — | — | — |
NCT04088786CT.gov Phase I Trial HIPEC With Nal-irinotecan | — | Completed | — | — | — |
NCT04833036CT.gov c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI | — | Unknown | — | — | — |
NCT04068610CT.gov COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC | — | Active Not Recruiting | — | — | — |
NCT04324476CT.gov A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT04368507CT.gov To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients | — | Completed | — | — | — |
NCT04008030CT.gov A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) | — | Active Not Recruiting | — | — | — |
NCT04160416CT.gov mXELOXIRI Combined With Molecular Targeted Drug in mCRC | — | Unknown | — | — | — |
NCT03366155CT.gov Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver | — | Completed | — | — | — |
NCT03829410CT.gov Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation | — | Completed | — | — | — |
NCT03798626CT.gov Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | — | Completed | — | — | — |
NCT03872947CT.gov A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03829462CT.gov Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients | — | Active Not Recruiting | — | — | — |
NCT04499586CT.gov A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer | — | Unknown | — | — | — |
NCT03750786CT.gov A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT03721653CT.gov FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients | — | Completed | — | — | — |
NCT03692429CT.gov alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells | — | Recruiting | — | — | — |
NCT03795311CT.gov Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3) | — | Active Not Recruiting | — | — | — |
NCT03693807CT.gov A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | — | Completed | — | — | — |
NCT03428958CT.gov A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | — | Completed | — | — | — |
NCT03608046CT.gov Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer | — | Unknown | — | — | — |
NCT03555149CT.gov A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | — | Terminated | — | — | — |
NCT03475004CT.gov Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | — | Completed | — | — | — |
NCT03376659CT.gov Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | — | Terminated | — | — | — |
NCT03645187CT.gov Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT03169777CT.gov QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | — | Withdrawn | — | — | — |
NCT03686254CT.gov The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM | — | Unknown | — | — | — |
NCT03491709CT.gov A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC | — | Unknown | — | — | — |
NCT03597581CT.gov A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT03668418CT.gov Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos | — | Unknown | — | — | — |
NCT05540951CT.gov VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT03500874CT.gov Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM | — | Terminated | — | — | — |
NCT03545711CT.gov Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT03604653CT.gov Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers | — | Completed | — | — | — |
NCT03186326CT.gov Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer | — | Completed | — | — | — |
NCT03396926CT.gov Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer | — | Completed | — | — | — |
NCT03493048CT.gov Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM | — | Active Not Recruiting | — | — | — |
NCT03374254CT.gov Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651) | — | Completed | — | — | — |
NCT03493061CT.gov A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM | — | Completed | — | — | — |
NCT03368963CT.gov TAS102 in Combination With NAL-IRI in Advanced GI Cancers | — | Active Not Recruiting | — | — | — |
NCT03391934CT.gov Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT02997228CT.gov Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study | — | Active Not Recruiting | — | — | — |
NCT05316818CT.gov Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma | — | Completed | — | — | — |
NCT03290937CT.gov Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT03206151CT.gov CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02982694CT.gov Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer | — | Terminated | — | — | — |
NCT03279289CT.gov Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen | — | Completed | — | — | — |
NCT03176264CT.gov PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer | — | Terminated | — | — | — |
NCT03263429CT.gov Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer | — | Completed | — | — | — |
NCT03184870CT.gov A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03117972CT.gov Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels | — | Terminated | — | — | — |
NCT03222089CT.gov Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC | — | Withdrawn | — | — | — |
NCT02873195CT.gov Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT03185988CT.gov Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System | — | Unknown | — | — | — |
NCT02758951CT.gov Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases | — | Active Not Recruiting | — | — | — |
NCT03050814CT.gov Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 | — | Terminated | — | — | — |
NCT03126071CT.gov Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT03504618CT.gov Research on the Treatment of Metastatic Colon Cancer Patients Treated by FOLFOXIRI | — | Completed | — | — | — |
NCT03035253CT.gov A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT03053167CT.gov Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients | — | Unknown | — | — | — |
NCT04034459CT.gov FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC | — | Unknown | — | — | — |
NCT02970916CT.gov Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms | — | Completed | — | — | — |
NCT02978313CT.gov Cetuximab Monotherapy Maintenance Treatment in mCRC | — | Unknown | — | — | — |
NCT03288987CT.gov Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02876224CT.gov Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors | — | Completed | — | — | — |
NCT05178745CT.gov Resection Observatory | — | Completed | — | — | — |
NCT02906059CT.gov Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02595931CT.gov M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | — | Active Not Recruiting | — | — | — |
NCT02785068CT.gov Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer | — | Withdrawn | — | — | — |
NCT02753127CT.gov A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02568046CT.gov Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients | — | Terminated | — | — | — |
NCT02591667CT.gov Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer | — | Unknown | — | — | — |
NCT02654639CT.gov Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT02624726CT.gov Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment | — | Unknown | — | — | — |
NCT02641873CT.gov A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02413853CT.gov Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer | — | Withdrawn | — | — | — |
NCT02386826CT.gov INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme | — | Completed | — | — | — |
NCT02515734CT.gov A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab | — | Unknown | — | — | — |
NCT02453464CT.gov A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT02573220CT.gov Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer | — | Withdrawn | — | — | — |
NCT02291289CT.gov A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | — | Completed | — | — | — |
NCT02934529CT.gov Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab | — | Completed | — | — | — |
NCT02316340CT.gov Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer | — | Completed | — | — | — |
NCT02292758CT.gov Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT02164916CT.gov S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02181556CT.gov Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02296203CT.gov Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). | — | Unknown | — | — | — |
NCT02162563CT.gov Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases | — | Completed | — | — | — |
NCT02173990CT.gov Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR). | — | Terminated | — | — | — |
NCT02141295CT.gov A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT02216487CT.gov Trial of FOLF(HA)Iri With Cetuximab in mCRC | — | Unknown | — | — | — |
NCT02129257CT.gov Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT01862003CT.gov Phase I/II Trial of Antagonism of HER in GI Cancer | — | Completed | — | — | — |
NCT02128425CT.gov FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT02688023CT.gov Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer | — | Unknown | — | — | — |
NCT02015754CT.gov Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer | — | Completed | — | — | — |
NCT01858662CT.gov Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors | — | Terminated | — | — | — |
NCT02605044CT.gov Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT01925274CT.gov A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT02071069CT.gov Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT01834014CT.gov Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases | — | Completed | — | — | — |
NCT01803282CT.gov Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01802645CT.gov Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases | — | Unknown | — | — | — |
NCT01787500CT.gov Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT01652482CT.gov Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) | — | Completed | — | — | — |
NCT01705002CT.gov Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. | — | Completed | — | — | — |
NCT01631539CT.gov Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC | — | Withdrawn | — | — | — |
NCT01506167CT.gov An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN) | — | Completed | — | — | — |
NCT02821559CT.gov Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01639326CT.gov Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1 | — | Unknown | — | — | — |
NCT01867697CT.gov Nordic 8 - A Phase II Trial | — | Completed | — | — | — |
NCT01523431CT.gov Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients | — | Completed | — | — | — |
NCT01531595CT.gov Study of Bevacizumab in Combination with Alternating XELIRI and XELOX in Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT01490866CT.gov A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) | — | Completed | — | — | — |
NCT01520389CT.gov Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment | — | Completed | — | — | — |
NCT01394939CT.gov Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma | — | Completed | — | — | — |
NCT01550510CT.gov Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA | — | Terminated | — | — | — |
NCT01479465CT.gov Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma | — | Terminated | — | — | — |
NCT01290783CT.gov Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC | — | Unknown | — | — | — |
NCT01478594CT.gov A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy | — | Completed | — | — | — |
NCT01399684CT.gov A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01451632CT.gov A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers | — | Completed | — | — | — |
NCT01367275CT.gov Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF | — | Terminated | — | — | — |
NCT01375816CT.gov Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT01326000CT.gov A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01328171CT.gov FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI) | — | Completed | — | — | — |
NCT01327612CT.gov Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) | — | Completed | — | — | — |
NCT01293942CT.gov IXO+A in mCRC With Liver-only Metastases | — | Withdrawn | — | — | — |
NCT01322152CT.gov Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT01304602CT.gov A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT01442935CT.gov Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases | — | Completed | — | — | — |
NCT01079780CT.gov Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy | — | Completed | — | — | — |
NCT01276379CT.gov Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab | — | Completed | — | — | — |
NCT01183780CT.gov A Study in Second Line Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01274624CT.gov Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01442649CT.gov Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab | — | Completed | — | — | — |
NCT01281761CT.gov Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) | — | Completed | — | — | — |
NCT01229813CT.gov Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT01167725CT.gov Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer | — | Terminated | — | — | — |
NCT01139138CT.gov Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT01124630CT.gov Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments | — | Completed | — | — | — |
NCT01047293CT.gov RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma | — | Completed | — | — | — |
NCT01205711CT.gov Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01116271CT.gov Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec | — | Completed | — | — | — |
NCT01133990CT.gov FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT01280643CT.gov Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT01060423CT.gov TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer | — | Terminated | — | — | — |
NCT01071655CT.gov Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT01075048CT.gov ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01016860CT.gov OSI-906 and Irinotecan in Patients With Advanced Cancer | — | Terminated | — | — | — |
NCT01008475CT.gov EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00851045CT.gov Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00766220CT.gov Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver | — | Withdrawn | — | — | — |
NCT00959647CT.gov A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study | — | Completed | — | — | — |
NCT01030042CT.gov Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients | — | Completed | — | — | — |
NCT00967616CT.gov Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy | — | Completed | — | — | — |
NCT01004159CT.gov Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan | — | Terminated | — | — | — |
NCT00958386CT.gov Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA) | — | Completed | — | — | — |
NCT05278728CT.gov Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer | — | Completed | — | — | — |
NCT00969033CT.gov CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin | — | Terminated | — | — | — |
NCT00975897CT.gov Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT00925015CT.gov Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016) | — | Completed | — | — | — |
NCT01437618CT.gov First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00940303CT.gov OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00940758CT.gov Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy | — | Completed | — | — | — |
NCT01550055CT.gov Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00891930CT.gov Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab | — | Completed | — | — | — |
NCT00873756CT.gov A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00885885CT.gov Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases | — | Completed | — | — | — |
NCT00920868CT.gov XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib | — | Completed | — | — | — |
NCT00851136CT.gov A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g) | — | Completed | — | — | — |
NCT01068132CT.gov Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab. | — | Completed | — | — | — |
NCT01225744CT.gov Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy | — | Completed | — | — | — |
NCT00936832CT.gov Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery | — | Withdrawn | — | — | — |
NCT00875771CT.gov Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients | — | Completed | — | — | — |
NCT00827684CT.gov Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations | — | Completed | — | — | — |
NCT00838578CT.gov Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT00813605CT.gov QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma | — | Completed | — | — | — |
NCT00778830CT.gov Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) | — | Completed | — | — | — |
NCT00719199CT.gov Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer | — | Terminated | — | — | — |
NCT00777478CT.gov Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer | — | Unknown | — | — | — |
NCT00856375CT.gov NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer | — | Completed | — | — | — |
NCT00752570CT.gov A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma | — | Completed | — | — | — |
NCT00755534CT.gov Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC | — | Terminated | — | — | — |
NCT00755118CT.gov Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc | — | Terminated | — | — | — |
NCT00778102CT.gov A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT00779311CT.gov A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT00707889CT.gov Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT00852228CT.gov Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | — | Unknown | — | — | — |
NCT00594984CT.gov Phase I/II Combination With Irinotecan- Erbitux | — | Completed | — | — | — |
NCT00642603CT.gov A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT00636610CT.gov A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00681876CT.gov Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer | — | Terminated | — | — | — |
NCT00637091CT.gov Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions | — | Completed | — | — | — |
NCT00588900CT.gov Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab | — | Terminated | — | — | — |
NCT00535353CT.gov AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00614393CT.gov Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004) | — | Completed | — | — | — |
NCT00577109CT.gov A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer. | — | Withdrawn | — | — | — |
NCT00551213CT.gov A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003) | — | Completed | — | — | — |
NCT00569790CT.gov Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer | — | Completed | — | — | — |
NCT00497497CT.gov A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g) | — | Completed | — | — | — |
NCT00625651CT.gov Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00569335CT.gov Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer | — | Completed | — | — | — |
NCT00557102CT.gov Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung | — | Completed | — | — | — |
NCT00522665CT.gov Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer | — | Completed | — | — | — |
NCT00689624CT.gov Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer | — | Completed | — | — | — |
NCT00642577CT.gov A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT00513266CT.gov Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery | — | Unknown | — | — | — |
NCT00537823CT.gov Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement | — | Terminated | — | — | — |
NCT00475293CT.gov Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC | — | Completed | — | — | — |
NCT00492999CT.gov Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver | — | Active Not Recruiting | — | — | — |
NCT00478634CT.gov A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00454116CT.gov A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients | — | Completed | — | — | — |
NCT00437268CT.gov A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer | — | Completed | — | — | — |
NCT00436072CT.gov ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00433927CT.gov 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) | — | Unknown | — | — | — |
NCT00438737CT.gov Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer | — | Unknown | — | — | — |
NCT00396487CT.gov Tailored Treatment in Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT00384176CT.gov First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX | — | Completed | — | — | — |
NCT00392470CT.gov Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer | — | Unknown | — | — | — |
NCT00532909CT.gov Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00671372CT.gov A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00323011CT.gov FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer | — | Terminated | — | — | — |
NCT00327093CT.gov Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases | — | Terminated | — | — | — |
NCT00316745CT.gov IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer | — | Suspended | — | — | — |
NCT00332163CT.gov Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy | — | Completed | — | — | — |
NCT00449163CT.gov Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer | — | Terminated | — | — | — |
NCT00786643CT.gov Study of Gamma Interfereon in Metastatic Colorectal Carcinoma | — | Completed | — | — | — |
NCT00278889CT.gov Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX) | — | Completed | — | — | — |
NCT00290615CT.gov Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00284258CT.gov Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer | — | Completed | — | — | — |
NCT00271011CT.gov A Study of Mitomycin C, Irinotecan, and Cetuximab | — | Terminated | — | — | — |
NCT00408551CT.gov Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver | — | Unknown | — | — | — |
NCT00265850CT.gov Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00559741CT.gov Cetuximab and Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00252564CT.gov Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00556413CT.gov Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00507091CT.gov Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination | — | Completed | — | — | — |
NCT00286130CT.gov Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01131078CT.gov A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum | — | Completed | — | — | — |
NCT00265824CT.gov Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM) | — | Completed | — | — | — |
NCT00084721CT.gov Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00153998CT.gov Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM) | — | Completed | — | — | — |
NCT00254137CT.gov Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT00070434CT.gov S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum | — | Withdrawn | — | — | — |
NCT00233623CT.gov Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer | — | Withdrawn | — | — | — |
NCT00286000CT.gov High Dose Simplified Folfiri in Advanced Colorectal Cancer: a Multicentre Phase II Study | — | Completed | — | — | — |
NCT00208260CT.gov Intensified Chemotherapy in CRC After Resection of Liver Metastases | — | Completed | — | — | — |
NCT00209651CT.gov Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT00077233CT.gov FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum | — | Terminated | — | — | — |
NCT00819754CT.gov A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT00063960CT.gov Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer | — | Completed | — | — | — |
NCT00230399CT.gov Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00064181CT.gov Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00063141CT.gov Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer | — | Completed | — | — | — |
NCT00312000CT.gov Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma | — | Completed | — | — | — |
NCT00268398CT.gov Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases | — | Completed | — | — | — |
NCT00033306CT.gov BMS-247550 in Treating Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT00258232CT.gov Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00027833CT.gov Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT00026364CT.gov ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01219920CT.gov FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00048139CT.gov A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00048126CT.gov A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00020501CT.gov Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver | — | Completed | — | — | — |
NCT02118064CT.gov Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma | — | Completed | — | — | — |
NCT00030797CT.gov Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00020917CT.gov Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer | — | Completed | — | — | — |
NCT00021281CT.gov Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT00004870CT.gov Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer | — | Completed | — | — | — |
NCT00006269CT.gov Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer | — | Terminated | — | — | — |
NCT00006037CT.gov Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT00005076CT.gov Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT00003753CT.gov Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer | — | Completed | — | — | — |
NCT00003225CT.gov Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00034502CT.gov A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT00571740CT.gov Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer | — | Withdrawn | — | — | — |
NCT04446793CT.gov Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Irinotecan (this asset) | UNICANCER | Approved | BB · 67 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Irinotecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P4 | BBB · 78 |
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Irinotecan in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/irinotecan-colorectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →